Pulse Biosciences Begins Enrollment for Pivotal Atrial Fibrillation Trial

Pulse Biosciences (PLSE) has announced the enrollment of its first patients in a pivotal clinical trial for atrial fibrillation. This marks a significant step forward in the development of their treatment.